AB & B Biotech (02627.HK)

Executive Summary

AB & B Biotech is a China-based vaccine developer leveraging proprietary subunit platforms to address infectious diseases. The company has advanced a quadrivalent influenza vaccine into Phase 3 trials, leveraging a patented process for enhanced immunogenicity. Concurrently, it is developing candidates for monkeypox, pneumococcal disease, and next-generation mRNA vaccines. As a public company (02627.HK) with $360M raised and 200-500 employees, AB&B is positioned to capitalize on China's growing vaccine market and global outbreak preparedness needs. The Phase 3 influenza vaccine data readout and potential regulatory submission are key near-term value drivers, while mRNA platform progress could unlock longer-term optionality. Given the early stage and competitive landscape, conviction is tempered by execution risk and regulatory uncertainty.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 influenza vaccine top-line data75% success
• Q1 2027BLA submission for influenza vaccine in China60% success
• H2 2027Proof-of-concept data for mRNA vaccine platform50% success